---
id: HSV-encephalitis-temporal-lobe_159
category: radiology
tags: [HSV-encephalitis, temporal-lobe, MRI, FLAIR, CNS-infection, acyclovir]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## HSV Encephalitis - Temporal Lobe Involvement

**Q:** What are the characteristic MRI findings of HSV encephalitis including temporal lobe involvement, and why is early empiric acyclovir critical?

**A:**

## DEFINITION

**HSV Encephalitis:** **"Acute necrotizing encephalitis caused by Herpes Simplex Virus (HSV-1 >90%), with predilection for temporal lobes and limbic system"**

**MRI Hallmark:** **Bilateral asymmetric T2/FLAIR hyperintensity involving medial temporal lobes, insular cortex, and inferior frontal lobes**

**Key Point:** **Temporal lobe involvement = HSV encephalitis** (until proven otherwise)

---

## PATHOPHYSIOLOGY

**Organism:** ***Herpes Simplex Virus Type 1*** (HSV-1) - 90-95% of cases

**Mechanism:**
1. **Reactivation** of latent HSV-1 (trigeminal ganglion) - most common
2. **Primary infection** (rare, usually children/young adults)
3. **Hematogenous spread** or **retrograde axonal transport** (olfactory/trigeminal nerve)
4. **Limbic system involvement** (temporal lobes, insular cortex, orbitofrontal cortex, cingulate gyrus)
5. **Necrotizing hemorrhagic encephalitis**

**Key Point:** **Reactivation of latent HSV-1 = most common** (not primary infection)

---

## MRI FINDINGS

**Hallmark: Bilateral Asymmetric Temporal Lobe T2/FLAIR Hyperintensity**

### **Mnemonic: "TEMPORAL LIMBIC"**

**T**emporal lobes (medial - **hallmark**, 90-100%)
**E**arly findings (subtle initially, may be normal first 48 hours)
**M**edial temporal structures (hippocampus, amygdala, parahippocampal gyrus)
**P**osterior orbital/inferior frontal lobes (60-80%)
**O**ften bilateral but asymmetric (70-80%)
**R**estricted diffusion (DWI bright - cytotoxic edema, early)
**A**symmetric (one side worse than other)
**L**imbic system (characteristic distribution)

**L**ocalized to temporal lobes initially
**I**nsular cortex (60-80%)
**M**ass effect (in severe cases)
**B**ilateral but asymmetric (characteristic)
**I**nferior frontal lobes (orbitofrontal cortex)
**C**ingulate gyrus (may be involved)

**Key Point:** **Bilateral asymmetric medial temporal lobes = HSV encephalitis**

---

## MRI SEQUENCE FINDINGS

### **FLAIR (Most Sensitive Early):**
- **Hyperintense signal** (bright) in medial temporal lobes
- **Bilateral but asymmetric**
- **Spares basal ganglia** (vs other encephalitis)
- **Involves hippocampus, amygdala, parahippocampal gyrus**
- **Most sensitive sequence** in first 72 hours

**Key Point:** **FLAIR = most sensitive early sequence** (shows abnormality before T2)

---

### **T2-Weighted:**
- **Hyperintense** medial temporal lobes
- **Bilateral asymmetric**
- **May involve insular cortex, inferior frontal**

---

### **DWI/ADC:**
- **DWI hyperintense** (bright - restricted diffusion)
- **ADC hypointense** (dark - cytotoxic edema)
- **Early finding** (within 24-48 hours)
- **Indicates acute phase** (active viral replication, cytotoxic injury)

**Key Point:** **Restricted diffusion = acute phase** (cytotoxic edema from active infection)

---

### **Post-Contrast T1:**
- **Enhancement** (variable, may be absent early)
- **Gyral enhancement** (if present, indicates blood-brain barrier breakdown)
- **Leptomeningeal enhancement** (adjacent to affected areas)
- **Not specific** (less useful than FLAIR/DWI)

---

### **T2* GRE or SWI (Susceptibility-Weighted):**
- **Hemorrhage** (blooming artifact - microhemorrhages)
- **Hemorrhagic component** in 50-70% (necrotizing encephalitis)
- **Temporal lobe petechial hemorrhages**

**Key Point:** **Hemorrhagic foci support HSV** (necrotizing hemorrhagic encephalitis)

---

## TEMPORAL EVOLUTION

**Day 0-2 (Very Early):**
- **May be NORMAL** (20-30% normal MRI in first 48 hours)
- **Subtle FLAIR hyperintensity** (if present)

**Day 2-7 (Early):**
- **FLAIR/T2 hyperintensity** (bilateral asymmetric temporal lobes)
- **Restricted diffusion** (DWI bright - cytotoxic edema)
- **Mild mass effect**

**Day 7-14 (Subacute):**
- **Progressive swelling** (mass effect, midline shift)
- **Hemorrhagic transformation** (T2* blooming)
- **Enhancement** appears (gyral, leptomeningeal)

**Week 2+ (Chronic):**
- **Atrophy** (temporal lobe volume loss)
- **Encephalomalacia** (tissue loss, cavitation)
- **Gliosis** (T2 hyperintensity persists)

**Key Point:** **Normal MRI in first 48 hours does NOT exclude HSV** (20-30% normal early)

---

## DISTRIBUTION PATTERN

**Characteristic Locations:**

1. **Medial temporal lobes** (90-100%) - **hallmark**
   - Hippocampus
   - Amygdala
   - Parahippocampal gyrus

2. **Insular cortex** (60-80%)

3. **Inferior frontal lobes** (60-80%)
   - Orbitofrontal cortex

4. **Cingulate gyrus** (40-60%)

**Spares:**
- **Basal ganglia** (usually spared)
- **Thalamus** (usually spared)
- **Posterior fossa** (cerebellum, brainstem - usually spared)

**Key Point:** **Limbic system involvement + spares basal ganglia/thalamus = HSV**

---

## CLINICAL PRESENTATION

**Classic Triad:**
1. **Fever** (90%)
2. **Altered mental status** (confusion, bizarre behavior, personality change)
3. **Seizures** (focal or generalized, 60-70%)

**Other Symptoms:**
- **Headache** (80-90%)
- **Focal neurologic deficit** (aphasia if dominant temporal, hemiparesis)
- **Memory impairment** (hippocampal involvement)
- **Olfactory/gustatory hallucinations** (temporal lobe involvement)

**Progression:**
- **Rapid** (hours to days)
- **Coma** (if untreated)

**Key Point:** **Altered mental status + seizures + fever = HSV encephalitis** (treat empirically)

---

## DIAGNOSIS

**Imaging:**
- **MRI with FLAIR + DWI** (diagnostic, 90-95% sensitive after 48 hours)

**CSF Analysis (Lumbar Puncture):**
- **WBC:** 10-500 (lymphocyte predominant, may have RBCs)
- **Protein:** 60-600 mg/dL (elevated)
- **Glucose:** Normal
- **RBCs:** Present (hemorrhagic CSF - **suggestive** of HSV)
- **HSV PCR:** **Gold standard** (95-98% sensitive, 99% specific)

**EEG:**
- **Periodic lateralized epileptiform discharges (PLEDs)** (70-80%)
- **Temporal lobe slowing**
- **Seizure activity**

**Key Point:** **HSV PCR from CSF = gold standard** (95-98% sensitive, 99% specific)

---

## HSV ENCEPHALITIS vs OTHER VIRAL ENCEPHALITIS

| **Feature** | **HSV Encephalitis** | **Arbovirus (WNV, EEE)** | **Autoimmune (NMDA)** |
|-------------|----------------------|--------------------------|------------------------|
| **Location** | **Temporal lobes (bilateral asymmetric)** | Basal ganglia, thalamus | Medial temporal lobes (bilateral symmetric) |
| **Hemorrhage** | **Common (50-70%)** | Less common | Absent |
| **CSF** | **Lymphocytic, RBCs** | Lymphocytic, no RBCs | Lymphocytic, no RBCs |
| **CSF PCR** | **HSV PCR positive** | Arbovirus IgM | NMDA receptor antibodies |
| **Treatment** | **Acyclovir** | Supportive | Immunotherapy |
| **Prognosis** | **Good if treated early** | Variable | Good with immunotherapy |

**Key Point:** **Temporal lobes + hemorrhagic CSF = HSV** | **Basal ganglia = arbovirus**

---

## TREATMENT

**EMPIRIC ACYCLOVIR IMMEDIATELY:**

**Indication:** **ANY suspected viral encephalitis** (don't wait for PCR result)

**Dosing:**
- **Acyclovir** 10 mg/kg IV q8h x 14-21 days
- **Start immediately** (before LP, before PCR result)

**Why Urgent:**
- **Mortality 70-80% if untreated**
- **Mortality 20-30% if treated**
- **Permanent neurologic sequelae 50-70% if delayed treatment**
- **Best outcomes if treated within 48 hours** of symptom onset

**Key Point:** **Start acyclovir IMMEDIATELY** (don't wait for confirmation - mortality 70% if untreated)

---

## ADJUNCTIVE THERAPY

**Anti-Seizure Medications:**
- **Levetiracetam** or **phenytoin** (if seizures)
- **Prophylactic** (even without seizures, 60-70% have seizures)

**Anti-Edema:**
- **Osmotic therapy** (mannitol, hypertonic saline if severe edema)
- **Avoid steroids** (no proven benefit, may worsen viral replication)

**ICP Monitoring:**
- **If severe edema** (GCS <8, mass effect)

**Key Point:** **Acyclovir + anti-seizure meds + supportive care**

---

## PROGNOSIS

**Mortality:**
- **Untreated:** 70-80%
- **Treated:** 20-30%

**Neurologic Outcome (Survivors):**
- **Full recovery:** 10-20%
- **Mild-moderate sequelae:** 30-40% (memory impairment, personality change)
- **Severe sequelae:** 40-50% (severe cognitive deficits, epilepsy, vegetative state)

**Predictors of Poor Outcome:**
1. **Delayed treatment** (>48 hours from symptom onset)
2. **GCS <6 at presentation** (coma)
3. **Age >50 years**
4. **Bilateral extensive involvement**
5. **Hemorrhagic transformation**

**Key Point:** **Early treatment (<48 hours) = best outcomes** (full recovery 40% if early vs 10% if delayed)

---

## COMPLICATIONS

**Mnemonic: "SEIZURE-MEMORY"**

**S**eizures (chronic epilepsy - 20-30% of survivors)
**E**ncephalomalacia (tissue loss, atrophy)
**I**ntellectual disability (cognitive deficits)
**Z**oning out (persistent altered mental status)
**U**ncontrolled ICP (cerebral edema, herniation)
**R**elapse (rare, <5%)
**E**nduring deficits (permanent)

**M**emory impairment (anterograde amnesia - hippocampal damage)
**E**pilepsy (chronic seizures)
**M**otor deficits (hemiparesis)
**O**rganized (gliosis, encephalomalacia)
**R**efractory seizures (30-40% develop epilepsy)
**Y**ielding poor quality of life

**Key Point:** **Memory impairment most common residual deficit** (hippocampal damage)

---

## DIFFERENTIAL DIAGNOSIS OF TEMPORAL LOBE LESIONS

**Mnemonic: "TEMPORAL LESIONS"**

**T**oxoplasmosis (HIV, basal ganglia more common)
**E**ncephalitis (HSV, autoimmune)
**M**etastases (usually multiple, enhancement)
**P**rimary brain tumor (glioma - unilateral)
**O**ther viral (CMV, VZV - immunocompromised)
**R**adiation necrosis (post-RT history)
**A**utoimmune (NMDA receptor encephalitis - bilateral symmetric)
**L**ymphoma (primary CNS - enhancement, immunocompromised)

**L**imbic encephalitis (paraneoplastic, autoimmune)
**E**pilepsy (temporal lobe epilepsy - chronic T2 hyperintensity)
**S**troke (vascular territory, acute onset)
**I**nfarct (posterior cerebral artery territory)
**O**ther infection (TB, fungal)
**N**MDA receptor encephalitis (bilateral symmetric, psychiatric symptoms)
**S**eizure-related (prolonged seizure â†’ edema)

**Key Point:** **Bilateral asymmetric temporal + hemorrhagic + acute = HSV**

---

**Clinical Pearls:**
- **Bilateral asymmetric medial temporal lobes on FLAIR/T2 = HSV encephalitis**
- **FLAIR = most sensitive early sequence** (shows abnormality before T2)
- **Normal MRI in first 48 hours does NOT exclude HSV** (20-30% normal early)
- **Restricted diffusion (DWI bright, ADC dark) = acute phase** (cytotoxic edema)
- **Hemorrhagic foci (T2* blooming) = necrotizing hemorrhagic encephalitis (HSV)**
- **CSF: Lymphocytic pleocytosis + RBCs + HSV PCR positive = diagnostic**
- **Altered mental status + seizures + fever = start acyclovir IMMEDIATELY**
- **Acyclovir 10 mg/kg IV q8h x 14-21 days** (start before PCR result)
- **Mortality 70-80% untreated, 20-30% treated**
- **Early treatment (<48 hours) = best outcomes** (40% full recovery vs 10% if delayed)
- **Memory impairment most common residual deficit** (hippocampal damage)
- **Spares basal ganglia/thalamus** (vs arbovirus encephalitis)

**Media:**

**Additional Resources:**
- **Radiopaedia.org:** Search "HSV encephalitis," "herpes simplex encephalitis"
- **PMC:** HSV encephalitis imaging and outcomes
- **IDSA Guidelines:** Encephalitis management

**Sources:** [Radiopaedia - HSV Encephalitis], [IDSA Encephalitis Guidelines], [PMC - HSV Encephalitis Outcomes]
